Mayo Clinic researchers are reporting a "pronounced reduction" this summer in the effectiveness of the Pfizer COVID-19 vaccine at preventing coronavirus infections, but still a high level of protection against severe illnesses and hospitalizations.
Examining records for 25,000 vaccinated and unvaccinated Mayo patients in Minnesota, the researchers reported 76% effectiveness in the Pfizer vaccine protecting them from infection this year, but only 42% effectiveness in July amid the emergence of a more transmissible delta variant. The comparable effectiveness of the Moderna vaccine declined from 86% to 76%.
The study authors remained bullish about COVID-19 vaccines, noting that the Pfizer version's effectiveness against hospitalizations was 75% in July, and that the Moderna vaccine's rate was 81%. The two-dose vaccines received federal emergency authorization in December based on their abilities to prevent severe illnesses; initial trials hadn't even explored whether they also prevented mild or asymptomatic infections.
"This study further supports the effectiveness of both vaccines … despite the evolution of more transmissible viral variants," said the study, co-authored by COVID-19 experts at Mayo and nference, a data partner in Massachusetts.
The effectiveness of the Pfizer and Moderna vaccines at preventing hospitalizations was 85% and 91%, respectively, during the entire year, so their performance in July alone was slightly worse.
The study did not assess the effectiveness of the single-dose Johnson & Johnson vaccine, which was approved later and has been used less in Minnesota. The state on Thursday reported that more than 6 million COVID-19 vaccine doses have been administered to more than 3.2 million eligible people 12 and older.
Pfizer's vaccine made up 57% of the doses administered. Johnson & Johnson's version made up 4.5%.
The study posted Monday on medRxiv has not undergone peer review. News of its findings emerged Thursday as Minnesota leaders celebrated a vaccination milestone — more than 70% of people 16 and older have received at least first doses in the state.